Familial thyroid carcinoma: A diagnostic algorithm

Advances in Anatomic Pathology

Volumn 15, Issue 6, 2008, Pages 332-349

  Dotto, Jorge ^a,b   Nosé, Vânia ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Familial adenomatous polyposis; Familial medullary thyroid carcinoma; Familial nonmedullary thyroid carcinoma; Familial papillary thyroid carcinoma; Familial thyroid carcinoma; Follicular carcinoma; Medullary thyroid carcinoma; Papillary thyroid carcinoma

Indexed keywords

CALCITONIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADENOMATOUS POLYP; ANAPLASTIC CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARNEY COMPLEX; CELL HYPERPLASIA; COWDEN SYNDROME; FAMILIAL CANCER; GENE MUTATION; GOITER; HAMARTOMA; HUMAN; KIDNEY CARCINOMA; MULTIPLE ENDOCRINE NEOPLASIA; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; WERNER SYNDROME; ADULT; ALGORITHM; CLASSIFICATION; COLON POLYPOSIS; CONGENITAL TUMOR; FEMALE; GENETICS; MEDULLARY CARCINOMA; MIDDLE AGED; PAPILLARY CARCINOMA; SIPPLE SYNDROME; THYROID TUMOR;

ADENOMATOUS POLYPOSIS COLI; ADULT; ALGORITHMS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASTIC SYNDROMES, HEREDITARY; PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS;

EID: 55949131613     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31818a64af     Document Type: Review

References (96)

1. Robinson D, Orr T. Carcinoma of the thyroid and other diseases of the thyroid in identical twins. Arch Surg. 1955;70:923-928.
2. Nemec J, Soumar J, Zamrazil V, et al. Familial occurrence of differentiated non-medullary. Thyroid Carcinoma Oncol. 1975;32: 151-157.
3. Ries LAG, Melbert D, Krapcho M, et al. 2007 SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. http://seer. cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
5. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056-1060.
6. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 [see comments]. Cancer. 2004;83:2638-2648.
7. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004:257-261.
8. Bondeson L, Ljungberg O. Occult papillary thyroid carcinoma in the young and the aged. Cancer. 1984;53:1790-1792.
9. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985;56:531-538.
10. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol. 2006;13:69-75.
11. Baloch ZW, LiVolsi VA. Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. Expert Rev Mol Diagn. 2005;5: 573-584.
12. Mears L, Diaz-Cano SJ. Difference between familial and sporadic medullary thyroid carcinomas. Am J Surg Pathol. 2003;27:266-267.
13. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353: 1105-1113.
14. Wolfe HJ, DeLellis RA. Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab. 1981;10:351-365.
15. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer. 1996;77:750-756.
16. LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab. 1997;82:39-41.
17. Kondo T, Nakazawa T, Murata S, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol. 2007;38:1810-1818.
18. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
19. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol. 2005;16:163-172.
20. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
21. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13:3-16.
22. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148: 936-941.
23. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8:83-95.
24. Schmidt J, Derr V, Heinrich M, et al. BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol. 2007;31: 1337-1343.
25. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26: 1016-1023.
26. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326.
27. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71-77.
28. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662-669.
29. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med. 1996;335:943-951.
30. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 1996;56:2167-2170.
31. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
32. Komminoth P, Kunz EK, Matias-Guiu X, et al. Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer. 1995;76:479-489.
33. Matias-Guiu X. RET protooncogene analysis in the diagnosis of medullary thyroid carcinoma and multiple endocrine neoplasia type II. Adv Anat Pathol. 1998;5:196-201.
34. Dvorakova S, Vaclavikova E, Sykorova V, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008;284:21-27.
35. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93: 682-687.
36. Carney JA. Familial multiple endocrine neoplasia: the first 100 years. Am J Surg Pathol. 2005;29:254-274.
37. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular cell neoplasms. Nat Rev Cancer. 2006;6:292-306.
38. Harach HR, Williams GT, Williams ED. Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology. 1994;25:549-561.
39. Soravia C, Sugg SL, Berk T, et al. Familial adenomatous polyposisassociated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol. 1999;154:127-135.
40. Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol. 1999;12:400-411.
41. Herraiz M, Barbesino G, Faquin W, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol. 2007; 5:367-373.
42. Chung DC, Maher MM, Faquin WC. Case records of the Massachusetts General Hospital. Case 37-2006. A 19-year-old woman with thyroid cancer and lower gastrointestinal bleeding. N Engl J Med. 2006;355:2349-2357.
43. Dotto J, Faquin W, Sadow P, et al. Familial non-medullary thyroid carcinoma. Morphologic patterns indicating an inherited trait. Mod Pathol. 2008;21:106A.
44. Harach HR, Soubeyran I, Brown A, et al. Thyroid pathologic findings in patients with Cowden disease. Ann Diagnost Pathol. 1999;3:331-340.
45. Zambrano E, Holm I, Glickman J, et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated diseases. Endoc Pathol. 2004;15:55-64.
46. Harach HR, Lesueur F, Amati P, et al. Histology of familial thyroid tumours linked to a gene mapping to chromosome 19p13.2. J Pathol. 1999;189:387-393.
47. Lachlan KL, Lucassen AM, Bunyan D, et al. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007;44: 579-585.
48. Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney Complex). J Clin Endocr Metab. 1997;82:2037-2043.
49. Stratakis CA, Kirschner LS, Taymans SE, et al. Carney complex, Peutz-Jeghers syndrome, Cowden disease, and Bannayan-Zonana syndrome share cutaneous and endocrine manifestations, but not genetic loci. J Clin Endocr Metab. 1998;83:2972-2976.
50. Goto M, Miller RW, Ishikawa Y, et al. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomark Prevent. 1996;5:239-246.
51. Ishikawa Y, Sugano H, Matsumoto T, et al. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer. 1999;85:1345-1352.
52. Nehlin JO, Skovgaard GL, Bohr VA. The Werner syndrome. A model for the study of human aging. Ann N Y Acad Sci. 2000;908: 167-179.
53. Fagin JA. Familial nonmedullary thyroid carcinoma - the case for genetic susceptibility. J Clin Endocrinol Metab. 1997;82: 342-344.
54. DeLellis RA. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features. Lab Invest. 1995;72: 494-505.
55. Biscolla RP, Ugolini C, Sculli M, et al. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid. 2004;14:946-952.
56. Yang GC, Yao JL, Feiner HD, et al. Lipid-rich follicular carcinoma of the thyroid in a patient with McCune-Albright syndrome. Mod Pathol. 1999;12:969-973.
57. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiple affected kindreds. Thyroid. 2006;16:181-186.
58. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:5747-5753.
59. Leprat F, Bonichon F, Guyot M, et al. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families. Clin Endocrinol. 1999;50:589-594.
60. Musholt TJ, Musholt PB, Petrich T, et al. Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg. 2000;24:1409-1417.
61. Ron E, Kleinerman RA, LiVolsi VA, et al. Familial nonmedullary thyroid cancer. Oncology. 1991;48:309-311.
62. Sturgeon C, Clark OH. Familial nonmedullary thyroid cancer. Thyroid. 2005;15:588-593.
63. Uchino S, Noguchi S, Kawamoto H, et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg. 2002;26:897-902.
64. Alsanea O, Wada N, Ain K, et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery. 2000;128:1043-1050, discussion 1050-1051.
65. Grossman RF, Tu SH, Duh QY, et al. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg. 1995;130:892-897; discussion 898-899.
66. Lupoli G, Vitale G, Caraglia M, et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet. 1999;353:637-639.
67. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Cancer Control. 2006;13:106-110.
68. Malchoff CD, Sarfarazi M, Tendler B, et al. Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. Thyroid. 1999;9:247-252.
69. Takami H, Ozaki O, Ito K. Familial nonmedullary thyroid cancer: an emerging entity that warrants aggressive treatment. Arch Surg. 1996;131:676.
70. Triponez F, Wong M, Sturgeon C, et al. Does familial nonmedullary thyroid cancer adversely affect survival? World J Surg. 2006;30: 787-793.
71. Brunaud L, Zarnegar R, Wada N, et al. Chromosomal aberrations by comparative genomic hybridization in thyroid tumors in patients with familial nonmedullary thyroid cancer. Thyroid. 2003;13: 621-629.
72. Bevan S, Pal T, Greenberg CR, et al. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1. J Clin Endocrinol Metab. 2001;86:3701-3704.
73. Burgess JR, Duffield A, Wilkinson SJ, et al. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid. J Clin Endocrinol Metab. 1997;82:345-348.
74. Lesueur F, Stark M, Tocco T, et al. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab. 1999;84:2157-2162.
75. Eng C. The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors. Recent Progr Hormone Res. 1999;54:441-452; discussion, 453.
76. Canzian F, Amati P, Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet. 1998;63:1743-1748.
77. Katoh R, Harach HR, Williams ED. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J Pathol. 1998;186: 292-299.
78. McKay JD, Williamson J, Lesueur F, et al. At least three genes account for familial papillary thyroid carcinoma: TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family. Eur J Endocrinol. 1999;141:122-125.
79. Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab. 2000;85:1758-1764.
80. McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69:440-446.
81. Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet. 1997;61:1123-1130.
82. Xing M. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Clin Endocrinol (Oxford). 2005;63:263-266.
83. Cetta F, Montalto G, Gori M, et al. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab. 2000;85:286-292.
84. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35-45.
85. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7:507-515.
86. Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22: 183-198.
87. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8:1461-1472.
88. Parisi MA, Dinulos MB, Leppig KA, et al. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet. 2001;38: 52-58.
89. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol. 2001;13:44-45.
90. Giacomelli L, Guerriero G, Falvo L, et al. Simultaneous occurrence of medullary carcinoma and papillary microcarcinoma of thyroid in a patient with MEN 2A syndrome. Report of a case. Tumori. 2007; 93:109-111.
91. Bakhsh A, Kirov G, Gregory GW, et al. A new form of familial multi-nodular goitre with progression to differentiated thyroid cancer. Endocr Relat Cancer. 2006;13:475-483.
92. Chiefari E, Russo D, Giuffrida D, et al. Analysis of RET protooncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest. 1998;21:358-364.
93. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575-1579.
94. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88: 1139-1148.
95. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349:1517-1525.
96. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619-1622.